Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ER+ tumorigenesis

Cell Death and Differentiation

Volumn 21, Issue 2, 2014, Pages 234-246

  Chan, S R ^a   Rickert, C G ^a   Vermi, W ^a,b   Sheehan, K C F ^a   Arthur, C ^a   Allen, J A ^a   White, J M ^a   Archambault, J ^a   Lonardi, S ^b   McDevitt, T M ^c   Bhattacharya, D ^a   Lorenzi, M V ^c,d   Allred, D C ^a   Schreiber, R D ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c BRISTOL MYERS SQUIBB   (United States)

^d Research and Development   (United States)

Author keywords

breast cancer; ERa; JAK2; PrlR; SOCS1; STAT1

Indexed keywords

ESTROGEN RECEPTOR ALPHA; JANUS KINASE 2; PROLACTIN RECEPTOR; STAT1 PROTEIN; STAT3 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; FUSED HETEROCYCLIC RINGS; JAK2 PROTEIN, MOUSE; N,N-DICYCLOPROPYL-4-((1,5-DIMETHYL-1H-PYRAZOL-3-YL)AMINO)-6-ETHYL-1-METHYL-1,6-DIHYDROIMIDAZO(4,5-D)PYRROLO(2,3B)PYRIDINE-7-CARBOXAMIDE; SOCS1 PROTEIN, MOUSE; STAT1 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST CELL; BREAST TUMOR; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DEATH; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; TUMOR CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CELL CULTURE; DEFICIENCY; DRUG EFFECTS; FEMALE; GENETICS; MAMMARY NEOPLASMS, ANIMAL; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

MUS;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; ESTROGEN RECEPTOR ALPHA; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; JANUS KINASE 2; MAMMARY NEOPLASMS, ANIMAL; MICE; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84892402949     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.116     Document Type: Article

References (56)

1. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
2. Tworoger SS, Hankinson SE. Prolactin and breast cancer etiology: an epidemiologic perspective. J Mammary Gland Biol Neoplasia 2008; 13: 41-53.
3. Walker SR, Nelson EA, Zou L, Chaudhury M, Signoretti S, Richardson A et al. Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res 2009; 7: 966-976.
4. Ormandy CJ, Hall RE, Manning DL, Robertson JF, Blamey RW, Kelly KA. Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J Clin Endocrinol Metab 1997; 82: 3692-3699. (Pubitemid 27509357)
5. Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C et al. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab 1998; 83: 667-674. (Pubitemid 28496555)
6. Cotarla I, Ren S, Zhang Y, Gehan E, Singh B, Furth PA. Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 2004; 108: 665-671. (Pubitemid 38076397)
7. Arendt LM, Schuler LA. Transgenic models to study actions of prolactin in mammary neoplasia. J Mammary Gland Biol Neoplasia 2008; 13: 29-40.
8. Iavnilovitch E, Cardiff RD, Groner B, Barash I. Deregulation of STAT5 expression and activation causes mammary tumors in transgenic mice. Int J Cancer 2004; 112: 607-619. (Pubitemid 39425940)
9. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998; 19: 225-268. (Pubitemid 29117815)
10. Liu X, Robinson GW, Wagner K-U, Garrett L, Wynshaw-Boris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 1997; 11: 179-186. (Pubitemid 27081895)
11. Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, Deng C-X et al. Inactivation of STAT5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol 2004; 24: 8037-8047. (Pubitemid 39167454)
12. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, rolds in cytokine responses. Cell 1998; 93: 841-850. (Pubitemid 28257589)
13. Wagner K-U, Krempler A, Triplett AA, Qi Y, George NM, Zhu J et al. Impaired alveologenesis and maintenance of secretory mammary epithelial cells in JAK2 conditional knockout mice. Mol Cell Biol 2004; 24: 5510-5520. (Pubitemid 38738182)
14. Han Y, Watling D, Rogers NC, Stark GR. JAK2 and STAT5, but not JAK1 and STAT1, are required for prolactin induced b-lactoglobulin transcription. Mol Endocrinol 1997; 11: 1180-1188. (Pubitemid 27278839)
15. David M, Petricoin EFr, Igarashi K, Feldman GM, Finbloom DS, Larner AC. Prolactin activates the interferon-regulated p91 transcription factor and the JAK2 kinase by tyrosine phosphorylation. Proc Natl Acad Sci USA 1994; 91: 7174-7178. (Pubitemid 24226825)
16. Gilmour KC, Reich NC. Receptor to nucleus signaling by prolactin and interleukin 2 via activation of latent DNA-binding factors. Proc Natl Acad Sci USA 1994; 91: 6850-6854. (Pubitemid 24226759)
17. DaSilva L, Rui H, Erwin RA, Howard OMZ, Kirken RA, Malabarba MG et al. Prolactin recruits STAT1, STAT3 and STAT5 independent of conserved receptor tyrosines TYR402, TYR479, TYR515 and TYR580. Mol Cell Endocrinol 1996; 117: 131-140. (Pubitemid 26118927)
18. Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM et al. STAT1-deficient mice spontaneously develop estrogen receptor a-positive luminal mammary carcinomas. Breast Cancer Res 2012; 14: R16.
19. Schneckenleithner C, Bago-Horvath Z, Dolznig H, Neugebauer N, Kollmann K, Kolbe T et al. Putting the brakes on mammary tumorigenesis: loss of STAT1 predisposes to intraepithelial neoplasias. Oncotarget 2011; 2: 1043-1054.
20. Klover PJ, Muller WJ, Robinson GW, Pfeiffer RM, Yamaji D, Hennighausen L. Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden. Neoplasia 2010; 12: 899-905.
21. Raven JF, Williams V, Wang S, Tremblay ML, Muller WJ, Durbin JE et al. Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle 2011; 10: 794-804.
22. Purandare AV, McDevitt TM, Wan H, You D, Penhallow B, Han X et al. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia 2012; 26: 280-288.
23. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
24. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA et al. Constitutive activation of STAT3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001; 20: 2499-2513. (Pubitemid 32531347)
25. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC et al. Targeted inhibition of STAT3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003; 100: 4138-4143. (Pubitemid 36418170)
26. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML et al. Generation of a functional mammary gland from a single stem cell. Nature 2006; 439: 84-88. (Pubitemid 43053633)
27. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D et al. Purification and unique properties of mammary epithelial stem cells. Nature 2006; 439: 993-997. (Pubitemid 43292419)
28. Van Keymeulen A, Rocha AS, Ousset M, Beck B, Bouvencourt G, Rock J et al. Distinct stem cells contribute to mammary gland development and maintenance. Nature 2011; 479: 189-193.
29. Tomic S, Chughtai N, Ali S. SOCS-1,-2,-3: selective targets and functions downstream of the prolactin receptor. Mol Cell Endocrinol 1999; 158: 45-54.
30. Helman D, Sandowski Y, Cohen Y, Matsumoto A, Yoshimura A, Merchav S et al. Cytokindinducible SH2 protein (CIS3) and JAK2 binding protein (JAB) abolish prolactin receptormediated STAT5 signaling. FEBS Lett 1998; 441: 287-291. (Pubitemid 29027912)
31. Pezet A, Favre H, Kelly PA, Edery M. Inhibition and restoration of prolactin signal transduction by suppressors of cytokind signaling. J Biol Chem 1999; 274: 24497-24502.
32. Ormandy CJ, Naylor M, Harris J, Robertson F, Horseman ND, Lindeman GJ et al. Investigation of the transcriptional changes underlying functional defects in the mammary glands of prolactin receptor knockout mice. Recent Prog Horm Res 2003; 58: 297-323. (Pubitemid 37339315)
33. Lindeman GJ, Wittlin S, Lada H, Naylor MJ, Santamaria M, Zhang J-G et al. SOCS1 deficiency results in accelerated mammary gland development and rescues lactation in prolactin receptor-deficient mice. Genes Dev 2001; 15: 1631-1636. (Pubitemid 32702585)
34. Harris J, Stanford PM, Sutherland K, Oakes SR, Naylor MJ, Robertson FG et al. Socs2 and Elf5 mediate prolactin-induced mammary gland development. Mol Endocrinol 2006; 20: 1177-1187.
35. Naka T, Fujimoto M, Tsutsui H, Yoshimura A. Negative regulation of cytokine and TLR signalings by SOCS and others. Adv Immunol 2005; 87: 61-122. (Pubitemid 41135899)
36. Sutherland KD, Lindeman GJ, Choong DY, Wittlin S, Brentzell L, Phillips W et al. Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 2004; 23: 7726-7733. (Pubitemid 39424931)
37. Yamaji D, Na R, Feuermann Y, Pechhold S, Chen W, Robinson GW et al. Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5A. Genes Dev 2009; 23: 2382-2387.
38. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces ERa-positive and ERa-negative mammary cancer in transgenic mice. Oncogene 2003; 22: 4664-4674. (Pubitemid 36976441)
39. Sakamoto K, Triplett AA, Schuler LA, Wagner KU. Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer. Oncogene 2010; 29: 5359-5369.
40. Frech MS, Halama ED, Tilli MT, Singh B, Gunther EJ, Chodosh LA et al. Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. Cancer Res 2005; 65: 681-685. (Pubitemid 40216421)
41. Caffarel MM, Zaragoza R, Pensa S, Li J, Green AR, Watson CJ. Constitutive activation of JAK2 in mammary epithelium elevates Stat5 signalling, promotes alveologenesis and resistance to cell death, and contributes to tumourigenesis. Cell Death Differ 2011; 19: 511-522.
42. Nevalainen MT, Xie J, Bubendorf L, Wagner KU, Rui H. Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium. Mol Endocrinol 2002; 16: 1108-1124. (Pubitemid 34478547)
43. Watson CJ, Neoh K. The Stat family of transcription factors have diverse roles in mammary gland development. Sem Cell Dev Biol 2008; 19: 401-406.
44. Liu X, Robinson GW, Hennighausen L. Activation of STAT5a and STAT5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation. Mol Endocrinol 1996; 10: 1496-1506. (Pubitemid 26408739)
45. Letourneur M, Valentino L, Travagli-Gross J, Bertoglio J, Pierre J. Sp2 regulates interferongamma-mediated socs1 gene expression. Mol Immunol 2009; 46: 2151-2160.
46. Saito H, Morita Y, Fujimoto M, Narazaki M, Naka T, Kishimoto T. IFN regulatory factor-1-mediated transcriptional activation of mouse STAT-induced STAT inhibitor-1 gene promoter by IFN-gamma. J Immunol 2000; 164: 5833-5843. (Pubitemid 30389827)
47. Clevenger CV, Zheng J, Jablonski EM, Galbaugh TL, Fang F. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics. J Mammary Gland Biol Neoplasia 2008; 13: 147-156.
48. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR et al. The JAK2/STAT3 signaling pathway is required for growth of CD44 CD24 stem cell-like breast cancer cells in human tumors. J Clin Invest 2011; 121: 2723-2735.
49. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009; 16: 487-497.
50. Britschgi A, Andraos R, Brinkhaus H, Klebba I, Romanet V, Muller U et al. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 2012; 22: 796-811.
51. Weaver BK, Bohn E, Judd BA, Gil MP, Schreiber RD. ABIN-3: a molecular basis for species divergence in interleukin-10-induced anti-inflammatory actions. Mol Cell Biol 2007; 27: 4603-4616. (Pubitemid 47016116)
52. Horvath CM, Wen Z, Darnell JE Jr. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev 1995; 9: 984-994.
53. Jin H, Lanning NJ, Carter-Su C. JAK2, but not Src family kinases, is required for STAT, ERK, and Akt signaling in response to growth hormone in preadipocytes and hepatoma cells. Mol Endocrinol 2008; 22: 1825-1841.
54. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253-1270. (Pubitemid 36583168)
55. Sheehan KCF, Schreiber RD. Generation and characterization of hamster monoclonal antibodies that neutralize murine necrosis factors. J. Immunol 1989; 142: 3884-3893. (Pubitemid 19164418)
56. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009; 347: 70-78.